Research Topics
| Martin FisherSummaryAffiliation: Royal Sussex County Hospital Country: UK Publications
| Collaborators
|
Detail Information
Publications
Acute hepatitis C: changing epidemiology and association with HIV infectionNick Brejt
Lawson Unit, The Royal Sussex County Hospital, Eastern Road, Brighton, East Sussex BN52 5BE, UK
J HIV Ther 12:3-6. 2007....- Brief communication: rituximab in HIV-associated multicentric Castleman diseaseMark Bower
Department of Oncology, Imperial College, The Chelsea and Westminster Hospital, Barts and The London NHS Trust, and Queen Mary s University, London, United Kingdom
Ann Intern Med 147:836-9. 2007..Many therapeutic approaches in small series of patients have proved largely unsuccessful to date... - Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years applicationMartin Fisher
Department of HIV and Genitourinary Medicine, Brighton and Sussex University Hospitals, Eastern Road, Brighton, BN2 5BE, UK
AIDS 21:2309-14. 2007..To investigate whether combining clinical data with the serological testing algorithm for recent HIV seroconversion (STARHS) reliably identifies otherwise unrecognized recent infections and observe their trends... - UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposureMartin Fisher
Department of Genitourinary Medicine, Royal Sussex County Hospital, Brighton, UK
Int J STD AIDS 17:81-92. 2006..Throughout the document, consideration is given to the place of PEPSE within the broader context of HIV prevention strategies and sexual health... 
Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approachMartin Fisher
HIV GUM Research Department, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
AIDS 24:1739-47. 2010..To identify biological factors associated with HIV transmission in men who have sex with men (MSM)...- Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infectionsDavid Pao
Department of GU Medicine, Brighton and Sussex University Hospitals, Brighton, UK
AIDS 19:85-90. 2005..More active identification of individuals during PHI, the management of STI and highly active antiretroviral therapy may all be useful methods to break transmission networks... - Long-term persistence of primary genotypic resistance after HIV-1 seroconversionDavid Pao
Royal Sussex County Hospital, Brighton, United Kingdom
J Acquir Immune Defic Syndr 37:1570-3. 2004.... - A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individualsMartin Fisher
Elton John Centre, Brighton and Sussex University Hospitals, Brighton, United Kingdom
J Acquir Immune Defic Syndr 51:562-8. 2009..Long-term antiretroviral therapy dramatically reduces HIV-related morbidity and mortality but is also associated with metabolic and morphological changes and requires high levels of adherence... - Potential impact of early antiretroviral therapy on transmissionDavid Pao
HIV GUM Research Department, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
Curr Opin HIV AIDS 4:215-21. 2009..We will focus on the biological plausibility and behavioural factors associated with HAART use and interventions that might influence such a strategy... 
Multicentre RCT and economic evaluation of a psychological intervention together with a leaflet to reduce risk behaviour amongst men who have sex with men (MSM) prescribed post-exposure prophylaxis for HIV following sexual exposure (PEPSE): a protocolCarrie Llewellyn
Brighton and Sussex Medical School, Brighton, UK
BMC Infect Dis 12:70. 2012..A secondary aim of this research is to examine the impact of the intervention on adherence to PEP. This study will also provide estimates of the cost-effectiveness of the intervention...- Immunological changes during treatment interruptions: risk factors and clinical sequelaeMary B Poulton
Brighton Health Care NHS Trust, Royal Sussex County Hospital, Brighton, East Sussex BN2 5BE, UK
AIDS 17:126-8. 2003 - Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practiceSara Louise Day
Brighton and Sussex University Hospitals, National Health Service Trust, Brighton, Sussex, United Kingdom
J Acquir Immune Defic Syndr 38:301-4. 2005..The etiology of HP seems to be multifactorial and unrelated to TDF or renal dysfunction. This questions the utility of routine phosphate testing, in isolation, in TDF recipients... - Preexposure prophylaxis for HIV infection: it's not as easy as ABCMartin Fisher
Department of HIV/Genitourinary Medicine, Brighton and Sussex University Hospitals, NHS Trust, Brighton, UK
Curr Opin Infect Dis 20:1-2. 2007 - Why some MSM present late for HIV testing: a qualitative analysisLucy Dowson
Brighton and Sussex Medical School, Brighton, UK
AIDS Care 24:204-9. 2012..Population-targeted health promotion alongside a more proactive approach by healthcare professionals and making HIV testing more convenient and accessible may result in earlier testing... - Home sampling kits for sexually transmitted infections: preferences and concerns of men who have sex with menSonali Wayal
Division of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK
Cult Health Sex 13:343-53. 2011..Home sampling kits could be a viable alternative to meet the increasing demand for sexual health services, but to improve the home sampling kit uptake the method of service provision must be culturally sensitive and acceptable... - Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behavioursMark Danta
UCL Institute of Hepatology, London, UK
AIDS 21:983-91. 2007..To characterize the mode of hepatitis C virus (HCV) transmission in a recent epidemic of acute HCV in HIV-infected individuals using linked molecular and clinical epidemiological studies... - Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns frameworkRobert Horne
Centre for Behavioural Medicine, Department of Policy and Practice, The School of Pharmacy, University of London, and Brighton University Hospital, National Health Service Trust, The Lawson Unit, United Kingdom
J Acquir Immune Defic Syndr 45:334-41. 2007..To test the utility of the necessity-concerns framework in predicting highly active antiretroviral therapy (HAART) uptake and adherence... - Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie
St Mary s Hospital, London, UK
AIDS 21:1423-30. 2007.... - Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infectionDaniel Richardson
J Infect Dis 197:1213-4, author reply 1214-5. 2008 - Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell countAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 21:1717-21. 2007..To assess the absolute rate of AIDS and death in antiretroviral therapy (ART)-naive patients with a high CD4 cell count. Such information would be helpful in the design of a trial investigating early initiation of ART... - Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3Kholoud Porter
Medical Research Council Clinical Trials Unit, London, United Kingdom
J Acquir Immune Defic Syndr 47:202-5. 2008.... - Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in womenInmaculada Jarrin
National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
Am J Epidemiol 168:532-40. 2008..74, 95% CI: 0.56, 0.98). Sex differences in HIV disease progression have become larger and statistically significant in the era of highly active antiretroviral therapy, supporting a stronger impact of health interventions among women... - Survival following HIV infection of a cohort followed up from seroconversion in the UKFiona M Ewings
MRC Clinical Trials Unit, London, UK
AIDS 22:89-95. 2008..To estimate changes over calendar time in survival following HIV seroconversion in the era of HAART and to provide updated survival estimates... - Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?Loveleen K Bansi
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London, NW3 2PF, UK
AIDS 22:349-56. 2008..We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression... - HIV and postexposure prophylaxisPaul Benn
Department of Genitourinary Medicine, Mortimer Market Centre, Camden PCT, London
Clin Med 8:319-22. 2008 - Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexityLorraine Sherr
Department of Primary Care and Population Sciences, Royal Free University College Medical School, London, UK
AIDS Care 20:442-8. 2008..42, p=0.01). The softer markers of adherence are not usually measured in follow up and may account for variations in treatment responses. The complexity of adherence needs to be understood and addressed to maximise treatment efficacy... - Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimenMike Youle
Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
J Acquir Immune Defic Syndr 29:58-61. 2002..Thus, a substantial proportion of patients who had failed to respond virologically to PI-containing regimens can achieve profound and sustained virologic suppression with a multidrug regimen... - A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)Chloe Orkin
The St Stephen's Centre, The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH
J Antimicrob Chemother 55:246-51. 2005..CONCLUSIONS: No differences in any analyses were observed between a standard of care regimen (zidovudine/lamivudine and efavirenz) and the quad regimen (zidovudine/lamivudine/abacavir and efavirenz)... - A balance of risks for the treatment of the chronically HIV-infected asymptomatic individualCeri Watson
Brighton University Hospital
Clin Med 3:212-6. 2003 - Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patientsCaroline A Sabin
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Antivir Ther 8:301-8. 2003..New formulations of amprenavir, together with boosted regimens, may enhance the activity in the presence of protease inhibitor-resistant virus... - Primary HIV Infection, phylogenetics, and antiretroviral preventionDeenan Pillay
J Infect Dis 195:924-6. 2007 - Changes in the risk of death after HIV seroconversion compared with mortality in the general populationKrishnan Bhaskaran
MRC Clinical Trials Unit, 222 Euston Rd, London NW1 2DA, United Kingdom
JAMA 300:51-9. 2008..Mortality among human immunodeficiency virus (HIV)-infected individuals has decreased dramatically in countries with good access to treatment and may now be close to mortality in the general uninfected population... - Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV SeroconvertersKrishnan Bhaskaran
Medical Research Council Clinical Trials Unit, London, UK
AIDS 18:1471-3. 2004..The virological and host determinants of this possible phenomenon are worth further exploration... - Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAARTRobert Horne
Centre for Health Care Research, Post Graduate Medical School, University of Brighton, Mayfield House, Falmer, Brighton BN1 9PH, UK
Int J STD AIDS 15:38-44. 2004..These preliminary findings suggest that patients' perceptions of HAART are important determinants of adherence with implications for future research and clinical practice... - Suicidal ideation in UK HIV clinic attendersLorraine Sherr
Royal Free and University College Medical School, London, UK
AIDS 22:1651-8. 2008..Although new treatments have changed prognosis, they also bring new challenges. This study measured suicidal ideation in HIV clinic attenders in the United Kingdom (London/Southeast) and explored associated factors... - Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trialWilliam Burman
Denver Public Health, 605 Bannock Street, Denver, CO 80204, USA
J Acquir Immune Defic Syndr 49:142-50. 2008..To compare the HIV transmission risk among patients randomized to episodic versus continuous antiretroviral therapy... - Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr
MRC Clinical Trials Unit, London, UK
Antivir Ther 13:675-85. 2008..The aim of this study was to examine factors influencing plasma concentration of efavirenz and nevirapine... - Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008.... - Joint-working. Worlds apartPat Gordon
Department of Organisational Research, London School of Economics
Health Serv J 113:28-9. 2003..Knowledge of each other's worlds was initially poor. Annual structured visits between PCTs and local authorities should be encouraged... - A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitisJacob Lalezari
Quest Clinical Research, San Francisco, California 94115, USA
J Acquir Immune Defic Syndr 30:392-400. 2002..Other than a higher than expected frequency of oral candidiasis (17%), no clinical toxicities or laboratory abnormalities occurred during treatment with valganciclovir that have not been observed during treatment with ganciclovir... - Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progressionCatharina E A Lindenburg
The Municipal Health Service of Amsterdam, Cluster Infectious Diseases, Amsterdam, The Netherlands
Vaccine 20:2343-7. 2002..98). In conclusion, therapeutic vaccination with p24-VLP is not related to slower HIV-1 disease progression... - Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppressionAndrew N Phillips
Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 18:1795-804. 2004..CONCLUSION: Viral rebound rates in patients who have attained < 50 copies/ml appear to differ according to the specific drugs being used... - Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenzFrank van Leth
Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Antivir Ther 9:721-8. 2004..To assess whether differences in safety profiles between nevirapine (NVP) and efavirenz (EFV), as observed in the 2NN study, translated into differences in 'health related quality of life' (HRQoL)... - Predictors of renal outcome in HIV-associated nephropathyFrank A Post
Academic Dept of HIV GUM, King s College London School of Medicine at Guy s, King s College, London, United Kingdom
Clin Infect Dis 46:1282-9. 2008..This study was performed to study the epidemiology of HIVAN in a predominantly black African population and the impact of highly active antiretroviral therapy and other factors on the development of end-stage renal disease... - Clinical standards for the screening and management of acquired syphilis in HIV-positive adultsRak Nandwani
The Sandyford Initiative, Glasgow and Brownlee Centre, Gartnavel General Hospital, Glasgow, UK
Int J STD AIDS 17:588-93. 2006..594-606]. Many of the recommendations remain in force and therefore the original document is published in full here... - A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2David Pao
AIDS 20:1564-5. 2006 - An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapyGraeme Moyle
Chelsea and Westminster Hospital, London, UK
Antivir Ther 11:73-8. 2006..To examine the antiviral potency and tolerability profile of a single-class four drug (quadruple) nucleoside reverse transcriptase inhibitor (NRTI) regimen compared with a 2-class standard-of-care regimen... - The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort studyColette J Smith
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
J Infect Dis 192:1387-97. 2005.... - Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practiceAndrew N Phillips
AIDS 19:487-94. 2005..3195% CI 0.15-0.61; p = 0.0008). CONCLUSION: In routine practice, rates of viral load failure and of resistance detection in patients who started ART with three or four drugs are appreciable... - Successive switching of antiretroviral therapy is associated with high psychological and physical burdenLorraine Sherr
Royal Free and University College Medical School, London, UK
Int J STD AIDS 18:700-4. 2007..A holistic approach is needed to understand the psychological effects of such switches if lifelong treatment is to be maintained and those on antiretroviral treatment are to attain good quality of life and minimize symptom burden... - Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort studyCaroline A Sabin
Department of Primary Care and Population Sciences, Royal Free and UC Medical School, London NW3 2PF
BMJ 330:695. 2005.... - Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Lancet 370:1923-8. 2007..We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure... - Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendationsMike Youle
Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
HIV Clin Trials 7:86-96. 2006..g., ENF) for triple-class-experienced patients... - Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapyGillian L Dean
St Thomas' Hospital, London, UK
AIDS 16:75-83. 2002..e. after 2 months) for patients who are clinically stable (CD4 > 100 x 106 cells/l)... - Late diagnosis of HIV infection: major consequences and missed opportunitiesMartin Fisher
Curr Opin Infect Dis 21:1-3. 2008 - TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individualsBrian Angus
Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK
AIDS 22:737-40. 2008..We aimed to see if structured treatment interruption (STI) could be supported safely with the use of two cycles of IL-2 (4.5 MIU q12h subcutaneously 5 days) before STI to prolong the time before therapy restarted... - Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick
Weill Cornell Medical College, New York, NY 10065, USA
N Engl J Med 359:1429-41. 2008..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...